Loading...
•
Mar 31, 2024
•/
Renalytix Q3 2024 Earnings Report
Renalytix's financial results for Q3 2024 were reported, highlighting progress in commercial adoption, expense reductions, and strategic initiatives.
Key Takeaways
Renalytix reported $0.5 million in revenue for Q3 2024, a decrease from $0.7 million in the same period last year. The company's operating expenses decreased to $6.5 million from $11.0 million year-over-year, and the net loss was $7.7 million, compared to $12.1 million in the prior year period. Cash and cash equivalents totaled $4.7 million as of March 31, 2024.
KidneyIntelX was included as the only biomarker test for prognostic risk assessment in a landmark update of international clinical practice guidelines.
A Medicare Local Coverage Determination draft was issued for FDA-authorized kidneyintelX.dkd by Medicare contractor National Government Services (NGS), with final issuance expected in the near term.
The formal launch of the FDA-authorized kidneyintelX.dkd occurred in April 2024.
Operating expense reduction continued with a 50% year-over-year reduction in head count and approximately 40% total lower operating costs.
Forward Guidance
The company did not provide specific forward guidance in the earnings report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...